25.04.2016 • News

Valeant on Verge of Hiring Perrigo’s CEO?

In its search for a new CEO to replace William J. Pearson, who has resigned amid several controversies, Canada-domiciled  embattled drugmaker Valeant is said to be finalizing a contract with Joseph C. Papa, chairman and CEO of Ireland-domiciled pharmaceutical producer Perrigo. Neither of the companies – both managed from the US – has been willing to comment on the speculation launched by The Wall Street Journal, which said the appointment could be announced as early as this week.

Valeant is under heavy scrutiny in the US Senate for price gouging. It also is being subjected to a US federal government audit of its accounting and pricing practices, as well more than one Securities and Exchange Commission (SEC) investigation.

Among other things, the SEC is looking into issues at Salix Pharmaceuticals, which was acquired by Valeant for $11 billion in 2015.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.